G6b-B bi-specific cis-acting platelet receptor inhibitors (CAPRIs) – a novel therapy in thrombosis

Amrita Sarkar, Ph.D.
Children’s Hospital of Philadelphia
Philadelphia, PA, U.S.

Amrita Sarkar, Ph.D., through this presentation discusses the team’s aim of investigating the efficacy and mechanistic basis of these bivalent CAPRIs in blocking prothrombotic disorders, such as heparin-induced thrombocytopenia (HIT), vaccine-induced immune thrombotic thrombocytopenia (VITT) and antiphospholipid syndrome (APS), in a human endothelial cell coated microfluidic system. Human umbilical vein endothelial cell-lined channels followed by photochemical injury were performed using microfluidics studies. These studies demonstrate that a CAPRI strategy targeting G6b-B through Fc RIIA is highly effective at preventing platelet accumulation.